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A B S T R A C T The agglutination of human platelets by ristocetin and von Willebrand factor was inhibited by aggregated immunoglobulin (Ig)G and by Fc fragments of IgG, but not by Fab, F(ab')2 or pFc fragments of IgG. Because this inhibition occurred with formalin-fixed platelets as well as with normal platelets, a generalized aggregation of fluid membrane components by Fc fragments was not responsible for this inhibition of ristocetin and von Willebrand factor-induced agglutination. Reciprocal inhibition of platelet Fc receptors was produced by prior incubation of platelets with von Willebrand factor and ristocetin. Sucrose density gradient ultracentrifugation studies demonstrated that aggregated IgG did not form fluid-phase complexes with von Willebrand factor and ristocetin. Furthermore, passage of von Willebrand factor and ristocetin through a column of immobilized heat-aggregated IgG did not alter platelet agglutinating activity which indicates that aggregated IgG did not inactivate von Willebrand factor or ristocetin. Thus, it was likely that the IgG-mediated interference with platelet agglutination by ristocetin and von Willebrand factor did not occur in the fluid phase but at the platelet surface. These studies suggest that the platelet membrane Fc receptor may be either a part of, or sterically related to, the membrane glycoprotein I complex that interacts with von Willebrand factor, and that occupation of one of these surface components blocks the availability of the other. INTRODUCTION Normal platelets in platelet-rich plasma, or formalinfixed platelets in the presence of normal plasma will agglutinate in response to the antibiotic ristocetin. The plasma factor that is required for this agglutination, von Willebrand factor, is part of the Factor VIII complex and is absent or diminished in patients with the inherited bleeding disorder, von Willebrand's disease (1) . Recent studies of the exact mechanism by which ristocetin supports von Willebrand factor-dependent platelet agglutination suggest that ristocetin and von Willebrand factor bind to the platelet and cause a reduction in net surface charge. This reduction in charge allows the large von Willebrand factor molecule to serve as an effective bridge between platelets, and agglutination occurs (2, 3) . A specific platelet surface membrane glycoprotein of mol wt 155,000, glycoprotein I, appears to be the mediator for the ristocetininduced von Willebrand factor-dependent platelet reaction (4) (5) (6) .
Soluble immune complexes and aggregated immunoglobulin (Ig)G also interact with washed platelets, causing aggregation and the release ofintracellular serotonin (7, 8) . The F(ab')2 fragments of IgG do not cause platelet aggregation, and preincubation of platelets with IgG Fc fragments blocks the aggregation induced by aggregated IgG (7, 9) . Platelet aggregation, under these circumstances, does not require complement components and appears to be initiated by the direct interaction of aggregated IgG or immune complexes with a platelet Fc receptor (7, 10) . In contrast to washed platelets, platelets in plasma do not aggregate or release serotonin in response to aggregated IgG. However, aggregated IgG does bind to platelets in plasma as well as to washed platelets or formalinfixed platelets (11, 12) .
In this present study, it was observed that aggregated IgG and, specifically, purified Fc fragments of IgG, 
METHODS
Platelet-rich plasma (PRP),1 platelet-poor plasma (PPP), and formalin-fixed washed platelets (FWP). Blood drawn from healthy volunteers was mixed with 0.1 vol of 3.2% sodium citrate in polypropylene tubes and centrifuged at 225 g for 10 min at room temperature to sediment leukocytes and erythrocytes. Platelet counts were performed with a Coulter Counter, model ZBI (Coulter Electronics Inc., Hialeah, Fla.), and the PRP was diluted with PPP to a platelet count of 200,000/,ul. PPP was prepared from PRP by centrifugation at 1,100 g for 20 min at room temperature. FWP were prepared from whole blood by the method of Grant et al. (13) and stored at 4 'C. For use in the microtiter aggregation assay, the FWP were resuspended in fresh PPP to a final concentration of 200,000/,ul.
Antisera. Rabbit antisera to human albumin, ceruloplasmin, fibrinogen, IgG, and a2-macroglobulin were obtained from Behring Diagnostics, American Hoechst Corp., Somerville, N. J. Antisera to IgA, IgM, and IgD were prepared by immunization of rabbits with myeloma proteins purified by starch block electrophoresis and Sephadex G-200 (Pharmacia Fine Chemicals, Piscataway, N. J.) column chromatography. The antisera to IgD, IgM, and IgA were absorbed with agarose-conjugated plasma proteins and shown to be specific for 8-, ,u-, and a-heavy chains. Antiserum to C3 was produced by immunization of rabbits with purified human C3 (14) . Antiserum to the hapten fluorescein isothiocyanate (FITC, Calbiochem, San Diego, Calif.) was prepared in rabbits immunized with carrier keyhole limpet hemocyanin (KLH, Calbiochem) conjugated to FITC at a molar ratio of 45:1. The IgG fraction of the antiserum to the KLH-FITC complex was made specific for the FITC hapten by absorption with the KLH carrier immobilized on agarose by the cyanogen bromide method (15) . The anti-FITC antibody was further purified by absorption and elution from FITC-human IgG conjugated to agarose. The anti-FITC was eluted by incubation with 3 M NH4SCN for 20 Hemofil, 3.86 iLg/ml, Profilate, 0.370 ,Lg/ml, and purified von Willebrand factor, 0.038 ,ug/ml. The purified von Willebrand factor, which was =95% pure on SDS-gel electrophoresis (20) was the same preparation used to follow Factor VIII antigen in the sucrose density gradient ultracentrifugation studies described below.
Agglutination studies with standard aggregation module. 0.45 ml vol ofPRP were stirred at 37°C in siliconized cuvettes in a Payton aggregation module (Payton Associates, Buffalo, N. Y.), and aggregating agents diluted in Tris-buffered saline, pH 7.35, were added. The responses were recorded on a Riken Denshi linear recorder (Payton Associates). For the studies of the inhibition of ristocetin agglutination, 40 jul of the test material or Tris-saline (control) was added to PRP at a stated time interval before ristocetin was added. In addition to the IgG and IgG fragments, purified human ceruloplasmin and bovine serum albumin (Sigma Chemical Co.) were used as controls. Ristocetin, 10 mg/ml (Abbott Diagnostics, Diagnostic Instruments, South Pasadena, Calif.), was added to the reaction mixture to give a final concentration of 1.09 mg/ml. ADP and collagen (Sigma Chemical Co.) were added to duplicate controls at the lowest concentrations which caused reproducible aggregation.
Agglutination studies with a microtiter plate. 0.225 ml vol of PRP or FWP resuspended in PPP were placed in the rounded well (1.6 ml capacity) of a siliconized-Lucite (E. I. DuPont de Nemours & Co., Inc., Wilmington, Del.) microtiter plate. 20 ,u of Tris-saline (control well) or ofthe preparation to be tested was added followed by 30 ul of ristocetin, 10 mg/ml (final concentration, 1.09 mg/ml). The plate was agitated by hand at room temperature for 3-5 min and the agglutination was recorded by visual and microscopic inspection with an inverted microscope.
Agglutination studies in a plasma-free system. 37.5 ,ul of a serially diluted sample of von Willebrand factor (Hemofil, Profilate, or purified Factor VIII), 37.5 id of the protein to be tested (bovine serum albumin, rabbit IgG, monomeric or aggregated human IgG, Fc fragment, Fab fragment, or pFc fragment, each at a final protein concentration of 0.7 mg/ml), 25 ,ul of ristocetin (final concentration, 0.3-0.4 mg/ml) and 100 p3 of FWP in PBS (final concentration, 100,000/,ul) were added to the well of a siliconized microtiter plate according to a modification ofthe method ofWeksler et al. (21) . The plate was agitated on a rotary shaker for 20 min at room temperature, and the agglutination recorded as above.
Serial dilutions of Fc fragments were also tested for inhibition of ristocetin agglutination in a similar system that incorporated fixed amounts of von Willebrand factor.
Sucrose density gradient ultracentrifugation of von Willebrand factor, ristocetin, and aggregated IgG. 5 IdI of 1251_ labeled heat-aggregated IgG (325 .ug/ml), consisting of dimers and trimers as determined by the method described above, were added to 75 ,ul of ristocetin, 10 mg/ml, and 25 ,ul of purified von Willebrand factor, 710,g/ml in PBS. After 10 min at room temperature, the sample was applied to a continuous 4.6-ml density gradient prepared with 10-40% sucrose in 0.01 M PBS, pH 7.4, and centrifuged at 32,000 rpm (122,000 g) for 18 (23) . After 30 min at room temperature, the gel was washed three times and examined for fluorescence with a Leitz Ortholux II microscope equipped with a Ploem illuminator (E. Leitz Inc., Rockleigh, N. J.).
1 ml of the aggregated IgG-gel was placed in a 1.8 x 8-cm column and equilibrated with PBS that contained 0.5 mg/ml of ristocetin and 1% human serum albumin (Miles Laboratories Inc.). Von Willebrand factor (Profilate, 140 ,ug in 200 pl) was placed on the column and eluted after 10 min with the ristocetin-albumin buffer into 0.5-ml fractions. 100-,uI samples of each eluted fraction were tested for von Willebrandfactor activity by a modification of the microtiter plate assay (21) and compared to similar fractions eluted from a control column of Bio-Gel A-5m agarose not conjugated to IgG.
Fluorescence assay for platelet Fc receptors. Platelets were washed according to the method of Pfueller et al. (12) , and labeled with soluble fluorescent immune complexes (KLH-anti-KLH) to detect the Fc receptor. The assay was a modification of a procedure described by Abbas and Unanue (24) for detection oflymphocyte Fc receptors. Both the antigen and the antibody were conjugated to FITC (1-2 ,ug FITC/ mg protein). A pellet of 1 x 108 washed platelets was resuspended in a mixture of 25 ,ul of KLH (100 ,ug/ml) and 25 ,u of anti-KLH (3 mg/ml), and incubated at room temperature for 30 min. The platelets were washed once by centrifugation through a 3-ml gradient of 2-4% bovine serum albumin in PBS at 600 g for 15 min. The pellet was resuspended and examined for fluorescence.
The fluorescent immune complexes stained -80-90% of normal platelets. With the majority of platelets, the staining pattern was "patchy" with one to three very fine fluorescent dots per platelet, and only an occasional platelet was stained in a crescent pattern that outlined a portion of the platelet periphery. With the method outlined above, excessive platelet clumping did not occur although there was occasional microscopic clumping which made exact quantitation difficult. The specificity ofthe staining reaction for Fc receptors was demonstrated by the inhibition of the staining reaction produced by prior incubation of the platelets with purified Fc fragments, 3 mg/ml. In addition, there was no platelet fluorescencestaining produced with either the FITC-conjugated antigen or antibody alone.
Inhibition of platelet Fc receptor staining by von Willebrand factor and ristocetin. 1 x 108 washed platelets were suspended in 70 Al of PBS which contained von Willebrand factor (Hemofil, 2.5 ,tg to 1 mg/ml) and 0.6 mg/ml ristocetin. Platelet agglutination was recorded after intermittent agitation for 10 min. Control preparations without ristocetin or without von Willebrand factor were tested simultaneously. In this system, the lowest concentration of von Willebrand factor which gave gross or microscopically detectable clumping in the presence of ristocetin was 5 ,ig/ml. The platelet preparations were then centrifuged at 1,000 g for 20 min, the supernate removed, and the platelets in the pellet resuspended and reacted with the KLH-anti-KLH reagent as described above.
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RESULTS
Inhibition of ristocetin-induced agglutination by whole rabbit antisera. Ristocetin-induced agglutination of platelets in PRP was blocked by the prior addition of a variety of different whole rabbit antisera (e.g., anti-IgG, -albumin, -1gM, -fibrinogen, -ceruloplasmin, or -a2-macroglobulin) but not by bovine serum albumin, or purified human ceruloplasmin. Blocking was dose dependent (Fig. la) , and occurred rapidly, even when the ristocetin was added immediately after the antiserum with no preincubation. Once the ristocetin-induced agglutination had started, it could be interrupted and partially reversed by the addition of an aliquot of antiserum (Fig. lb) 16 -fold increase in the concentration of von Willebrand factor was required to support ristocetin-induced platelet agglutination (Table II) . When a constant amount of von Willebrand factor was used in this system, Fc fragments produced a dose-dependent inhibition of ristocetin-induced platelet agglutination (Table III) .
Absence of IgG-ristocetin-von Willebrand factor complex formation in the fluid phase. To determine whether aggregated IgG inhibited the agglutination of platelets by forming a complex with von Willebrand factor and ristocetin in the fluid phase, sucrose density gradient analysis was performed with 1251-labeled heataggregated IgG before and after incubation with ristocetin and von Willebrand factor. The von Willebrand factor was followed by the location of immunoprecipitable Factor VIII antigen. Studies by others have shown that von Willebrand factor and Factor VIII antigen move together in sucrose density gradients in the presence or absence of ristocetin (25) . Dimers and trimers of IgG which were previously shown to inhibit von Willebrand factor and ristocetininduced agglutination of platelets, were selected for 125I-labeling because aggregates of this size were relatively small compared to von Willebrand factor/Factor VIII antigen and would sediment a much smaller distance than Factor VIII antigen in the sucrose density gradient. Therefore, if any complex formed between the aggregated IgG and von Willebrand factor in the presence or absence of ristocetin, it would be easily detectable by a shift of the radioactivity down the gradient toward the Factor VIII antigen.
The results of these experiments (Fig. 3) demonstrated that Factor VIII antigen was distributed into 4 The final concentration of von Willebrand factor in undiluted well was: Hemofil 7.9 mg/ml, Profilate 760 ,ug/ml, or purified Factor VIII 78 ug/ml. § The grading system is the same as in Table I .
"Eight preparations of increasing molecular weights (3 x 105 ->2 x 106) as determined by Sepharose CL-6B column chromatography were tested. All preparations were inhibitory. t The grading system is the same as in Table I. fraction 3 through 12 with the peak at fraction 8. This pattern was not changed by the presence of ristocetin (Fig. 3a) . The labeled aggregates of IgG were localized to fractions 9 through 27 with the peak at fraction 16. This pattern was unchanged by prior mixing of the aggregates IgG with von Willebrand factor, ristocetin, or a mixture of von Willebrand factor and ristocetin ( Fig. 3b and c (6, (30) (31) (32) . Studies that demonstrate interference of this reaction obtained with whole antisera or isolated IgG might require confirmation by experiments with the Fab or F(ab')2 fragments alone, as our results suggest that most rabbit antisera contain enough aggregated IgG or immune complexes to nonspecifically interfere with the agglutination reaction. In addition, the finding that occupation of the platelet Fc receptor blocks the reaction of ristocetin and von Willebrand factor with the platelet surface suggests the possibility that there may be some acquired abnormalities of ristocetin-induced platelet agglutination in clinical conditions associated with circulating immune complexes. In preliminary studies, we have observed absent platelet agglutination in response to ristocetin in the platelet-rich plasma of 4 of 12 patients with systemic lupus erythematosus.2 The refractoriness to ristocetin in such patients may be a result of occupation of the platelet Fc receptor by circulating immune complexes with subsequent masking of the von Willebrand factor receptor site.
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